Abstract
Coagulation function has often been viewed by clinicians as a protein mediated process cascading from one reaction to the next with an eventual outcome of solid clot. This view has been fostered by medical school teaching that has focused upon the coagulation cascades. The effects of platelet numbers and platelet function may be less well understood and monitored. The complexity of coagulation and its many nuances can be daunting.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Essell JH, Martin TJ, Salinas J, et al. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vase Anesth 7:410–415, 1993
Gertler JP, Abbott WM. Prothrombotic and fibrinolytic function of normal and perturbed endothelium. J Surg Res 52:89–95, 1992
Eisenberg PR, ed. Endothelial cell mediators of thrombosis and fibrinolysis. Coronary Artery Disease. 2:129–166, 1991
Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264:4743–4746, 1989
Spiess BD. Perioperative coagulation concerns: function, monitoring and therapy. Clinical Anesthesia Updates 4:1–16, 1993
Mollace V, Salvemini D, Sessa WC, Vane JR. Inhibition of human platelet aggregation by endothelium-derived relaxing factor, sodium nitroprusside or iloprost is potentiated by Captopril and reduced thiols. J Pharmacol Exp Ther 258:820–823, 1991
Lucore CL. Regulation of fibrinolysis by vascular endothelium. Coronary Artery Disease 2:157–166, 1991
Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 49:2533–2553, 1989
Van Hinsbergh VW, Binnema D, Scheffer MA, et al. Production of plasminogen activators and inhibitor by serially propagated endothelial cells from adult human blood vessels. Arteriosclerosis 7:389–400, 1987
Butler J, Rocker GM, Westaby S. Inflammatory responses to cardiopulmonary bypass. Ann Thorac Surg 55:552–559, 1993
Jansen NJ, VanOeveren W, Gu YJ, et al. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 54:744–748, 1992
Gu YJ, VanOeveren W, Boonstra PW, et al. Leukocyte activation with increased expression of CR3 receptors during cardiopulmonary bypass. Ann Thorac Surg 53:839–843, 1992
Menasché P, Peynet J, Larivière J, et al. Does normothermia during cardiopulmonary bypass increase neutrophil-endothelium interactions? Circulation 90:II275–279, 1994
Hynes RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell 69:11–25, 1992
Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorol 12 myristate 13 acetate and tumor necrosis factor. J Biol Chem 264:20705–20713, 1989
Schleef RR, Bevilacqua MP, Sawdey M, et al. Cytokine activation of vascular endothelium. J Biol Chem 263:5797–5803, 1988
Gouin I, Lecompte T, Morel MC. In-vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis. Circulation 85:935–941, 1992
Kowalski E, Kopec M, Wegrzynowicz Z. Influence of fibrinogen degredation products (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thromb Diatr Haemorr 10:406, 1963
VanHinsbergh VW. Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis 18:307–327, 1988
Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin and histamine. J Lab Clin Med 109:97–104, 1987
Erickson L, Ginsberg MH, Loskutoff DJ. An inhibitor of plasminogen activator in platelets. Haemostasis 14:65, 1984
Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of radioimmunoassay and observations on its plasma concentration during venous occlusion after platelet aggregation. Blood 70:1645–1653, 1987
Kluft C, Verheijen JH, Jie AF, et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue type plasminogen activator after trauma. Scand J Clin Lab Invest 45:605–610, 1985
Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2:3–9, 1987
Margaglione M, DiMinno G, Grandone E, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor −1 in patients with a history of ischemic stroke. Arterioscler Thromb 14:1741–1745, 1994
Cortellaro M, Cofrancesco E, Boschetti C, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. Arterioscl Thromb 13:1412–1417, 1993
Eriksson B, Eriksson E, Gyzander E, et al. Deep vein thrombosis after total hip replacement—relationship to the fibrinolytic system. Acta Orthop Scand 60:159–163, 1989
Larsson J, Risberg B. Fibrinolytic activity in human legs in tourniquet ischemia. Thromb Res 11:817–825, 1977
Mellbring G, Dahlgren S, Reiz S, et al. Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery. Thromb Res 32:575–584, 1983
Andreotti F, Davies GJ, Hackett D, et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 62:635–637, 1988
Tanaka K, Takao M, Yaka I, et al. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 3:181–188, 1989
Chandler WL, Fitch JCK, Wall MH, et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. J Thromb Hemost (submitted) 1995.
Andreasson S, Smith L, Aasen AO, et al. Local pulmonary activation of proteolytic enzymes after Escherichia-coli-induced lung injury in sheep. Eur Surg Res 20:289–297, 1988
Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 105:957–963, 1987
Marcus AJ. Thrombosis and inflammation as multicellular processes: pathophysiologic significance of transcellular metabolism. Blood 76:1903–1907, 1990
Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest 87:571–580, 1991
Del Maschio A, Evangelista V, Rajtar G, et al. Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am J Physiol 258:870–879, 1990
Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet function. Nature 255:720–722, 1975
Rinder CS, Bonan JL, Rinder HM, et al. Cardiopulmonary bypass induces leukocyte platelet adhesion. Blood 79:1201–1205, 1992
Rinder CS, Gaal D, Student LA, Smith BR. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 107:280–288, 1994
Simpson PJ, Todd RF III, Fantone JC, et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mol, anti-CDllb) that inhibits leukocyte adhesion. J Clin Invest 81:624–629, 1988
Wallis WJ, Beatty PG, Ochs HD, Harlan JM. Human monocyte adherence to cultured vascular endothelium: monoclonal antibody-defined mechanisms. J Immunol 135:2323–2330, 1985
Wright SD, Weitz JI, Huang AJ, et al. Complement receptor type three (CDllb/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci 85:7734–7738, 1988.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Spiess, B.D. (1996). The Interaction of Coagulation and Inflammation. In: Stanley, T.H., Bailey, P.L. (eds) Anesthesiology and the Cardiovascular Patient. Developments in Critical Care Medicine and Anesthesiology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-1622-7_12
Download citation
DOI: https://doi.org/10.1007/978-94-009-1622-7_12
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7224-3
Online ISBN: 978-94-009-1622-7
eBook Packages: Springer Book Archive